Engrail Therapeutics Stock

Engrail Therapeutics is a developer of medicines to transform the lives of patients with life-limiting diseases of the nervous system.

Sign up today and learn more about Engrail Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Engrail Therapeutics Stock

Engrail is forging a new direction to reduce the enormous burden of diseases that impact the nervous system. We unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverage our flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization.

Funding History

June 2020$32.0M
August 2021$32.0M
March 2024$157M

Management

Board Member

Jasper Bos

Co-Founder ,Executive VP & Chief Development Officer

Stephen Cunningham

Board Member

Stacie Weninger

Board Member

Tiba Aynechi

Co-Founder , President & CEO

Vikram Sudarsan

Chief Scientific Officer

Kimberly E. Vanover

Board Member

Peter Bisgaard

Board Member

Heath Lukatch

Board Member

Niall O'Donnell

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo